Ambrx Biopharma Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AMAM research report →
About the company
Ambrx Biopharma Inc. operates as a clinical-stage biotechnology company focused on the discovery and development of precisely engineered biologic medicines. The firm utilizes its unique expanded genetic code technology platform to create these advanced therapies.
- CEO
- Daniel J. O'Connor
- IPO
- 2023
- Employees
- 87
- HQ
- La Jolla, CA, US
Price Chart
- Market Cap
- $1.77B
- P/E
- -13.86
- P/S
- 239.41
- P/B
- 9.17
- EV/EBITDA
- -27.36
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -771.16%
- Net Margin
- -1053.72%
- ROE
- -50.68%
- ROIC
- -43.23%
- Revenue
- $7.40M · -0.71%
- Net Income
- $-77,996,000 · -14.22%
- EPS
- $-2.02 · 39.52%
- Op Income
- $-57,081,000
- FCF YoY
- -45.74%
- 52W High
- $28.15
- 52W Low
- $6.55
- 50D MA
- $25.33
- 200D MA
- $16.45
- Beta
- -2.36
- Avg Volume
- 1.94M
Get TickerSpark's AI analysis on AMAM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 11, 23 | O'Connor Daniel J. | other | 750,000 |
| Oct 27, 23 | O'Connor Daniel J. | sell | 50,012 |
| Oct 23, 23 | Cormorant Asset Management, LP | buy | 1,307,311 |
| Sep 18, 23 | Cormorant Asset Management, LP | buy | 751,233 |
| Sep 15, 23 | Cormorant Asset Management, LP | buy | 1,401,505 |
| Sep 1, 23 | DALESANDRO MARGARET | other | 125,000 |
| Sep 1, 23 | DALESANDRO MARGARET | other | 70,833 |
| Sep 1, 23 | DALESANDRO MARGARET | other | 0 |
| Jul 5, 23 | O'Connor Daniel J. | other | 1,216,500 |
| Jul 5, 23 | Nelson Sonja | other | 389,000 |
Our AMAM coverage
Recent articles, reports, and earnings notes.
No research on AMAM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AMAM report →Similar companies
Peers in the same neighborhood.